Navigation Links
Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Date:9/1/2009

TUSTIN, Calif., Sept. 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 at 10:25 am EDT. The conference will be held at the New York Palace Hotel in New York City.

A live webcast of the company's presentation will be available at the Investors section of Peregrine's website at www.peregrineinc.com. A replay will be available on the Peregrine website and archived for 90 days.

For more information about this conference, please visit: http://www.rodmanandrenshaw.com/conferences?id=30

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                               Media
    info@peregrineinc.com                                   Jennifer Anderson
    (800) 987-8256                                          (212) 918-4642


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
2. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
3. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
4. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
5. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
6. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
7. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
8. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
9. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
10. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
11. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017   Parent Project ... fight to end Duchenne muscular dystrophy (Duchenne) , ... the New Jersey Institute of Technology (NJIT) and Talem ... exploration of robotic technology to assist people living ... incorporate NJIT,s technology – an embedded computer, software, a ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on ... Valley Stream, NY. The procedure was an anterior cervical discectomy and fusion on ...
(Date:1/18/2017)... ... January 18, 2017 , ... Announced in December ... Institutes (MII). U.S. Secretary of Commerce Penny Pritzker has announced the award of ... of Defense has announced the award of a new Advanced Regenerative Manufacturing Institute ...
(Date:1/18/2017)... ... 2017 , ... Researchers from a new study are stating that if levels of ... cancer treatment, this indicates there is still remaining prostate cancer cells that are more likely ... test has always been an indicator of whether a man’s prostate cancer is growing ...
Breaking Biology Technology:
(Date:1/18/2017)... Minn. , Jan. 18, 2017 ... technology company that supports the entire spectrum of ... has been another record-breaking year for the organization ... market interest in MedNet,s eClinical products and services. ... the tremendous marketplace success of iMedNet ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... office of the future.  1,000 participants were simply asked which ... months which we may consider standard issue.  Insights on what ... 2017 were also gathered from futurists and industry leaders including ... James Canton .  Some of ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
Breaking Biology News(10 mins):